Bowden, Patrick http://orcid.org/0000-0002-5085-3322
See, Andrew W.
So, Kevin
Lawrentschuk, Nathan
Moon, Daniel http://orcid.org/0000-0002-8863-9727
Murphy, Declan G. http://orcid.org/0000-0002-7500-5899
Rao, Ranjit
Crosthwaite, Alan
King, Dennis
Haxhimolla, Hodo
Grummet, Jeremy
Ruljancich, Paul
Gyomber, Dennis
Landau, Adam
Campbell, Nicholas
Frydenberg, Mark
Smyth, Lloyd M. L. http://orcid.org/0000-0002-6675-5807
Nolan, Skye
Gwini, Stella M. http://orcid.org/0000-0002-0295-4575
McKenzie, Dean P. http://orcid.org/0000-0002-0006-9062
Clinical trials referenced in this document:
Documents that mention this clinical trial
68Ga-PSMA-PET screening and transponder-guided salvage radiotherapy to the prostate bed alone for biochemical recurrence following prostatectomy: interim outcomes of a phase II trial
https://doi.org/10.1007/s00345-021-03735-0
Funding for this research was provided by:
Epworth Medical Foundation
EJ Whitten Foundation
Article History
Received: 1 March 2021
Accepted: 13 May 2021
First Online: 2 June 2021
Declarations
:
: DGM has received honoraria for speaking and consulting activities from Astellas, Janssen, Bayer, Ferring, Ipsen and Astra Zeneca. The authors have no other conflicts of interest to declare that are relevant to the content of this article.
: This study was approved by the Epworth Human Research Ethics Committee (675–15; Phase II trial harnessing PSMA-PET and Calypso® real-time tracking to precisely locate and treat recurrent prostate cancer (PINPOINT)). This study was conducted in line with the principles of the Declaration of Helsinki and its later amendments or comparable ethical standards.
: All patients gave their informed and written consent to participate in this trial.
: Consent for publication was provided by all patients within the trial informed consent.